降低低密度脂蛋白胆固醇与载脂蛋白B的新兴疗法:JACC焦点研讨会1/4
在他汀、依折麦布和PCSK9抑制剂基础上,新型降LDL-C疗法正在研发用于心血管疾病预防。Inclisiran每年仅需给药两次,有望克服依从性障碍;Bempedoic acid为他汀不耐受患者提供替代;ANGPTL3抑制剂在纯合子家族性高胆固醇血症中强效降LDL-C且无洛美他派和米泊美生的主要不良反应;CETP抑制剂obicetrapib可能有效。这些药物为从一级预防到纯合子家族性高胆固醇血症患者提供降LDL-C工具。
要点
- Inclisiran每年两次给药,可能改善降脂治疗持久性和依从性。
- Bempedoic acid在他汀上游降LDL-C,适用于他汀不耐受患者。
- ANGPTL3抑制剂在纯合子家族性高胆固醇血症中强效降LDL-C且耐受性优于洛美他派和米泊美生。
核心结论
- 新型降LDL-C疗法为从一级预防到纯合子家族性高胆固醇血症患者提供有效降低LDL-C的工具。
研究设计与样本
- JACC焦点研讨会综述,评估在标准降脂治疗基础上新兴LDL-C降低疗法的开发与作用。
主要发现
- Inclisiran为抑制PCSK9的小干扰RNA,每年仅需给药两次。
- Bempedoic acid在他汀上游降低LDL-C,为他汀不耐受患者提供新选择。
- ANGPTL3抑制剂在纯合子家族性高胆固醇血症患者中强效降LDL-C,无洛美他派和米泊美生的主要不良反应,可能减少脂蛋白血浆置换需求。
- CETP抑制剂obicetrapib的开发可能使其有效。
临床怎么用
- Inclisiran可简化给药频率以改善长期依从性。
- Bempedoic acid可用于他汀不耐受患者的降LDL-C治疗。
- ANGPTL3抑制剂可用于纯合子家族性高胆固醇血症,可能减少血浆置换。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adding to the foundation of statins, ezetimibe and proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i), novel, emerging low-density lipoprotein cholesterol (LDL-C)-lowering therapies are under development for the prevention of cardiovascular disease. Inclisiran, a small interfering RNA molecule that inhibits PCSK9, only needs to be dosed twice a year and has the potential to help overcome current barriers to persistence and adherence to lipid-lowering therapies. Bempedoic acid, which lowers LDL-C upstream from statins, provides a novel alternative for patients with statin intolerance. Angiopoetin-like 3 protein (ANGPTL3) inhibitors have been shown to provide potent LDL-C lowering in patients with homozygous familial hypercholesterolemia without major adverse effects as seen with lomitapide and mipomersen, and may reduce the need for apheresis. Finally, CETP inhibitors may yet be effective with the development of obicetrapib. These novel agents provide the clinician the tools to effectively lower LDL-C across the entire range of LDL-C-induced elevation of cardiovascular risk, from primary prevention and secondary prevention to null-null homozygous familial hypercholesterolemia patients.
引用
- Nurmohamed NS, Navar AM, Kastelein JJP, et al. New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2021. PMID: 33766264. doi:10.1016/j.jacc.2020.11.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。